Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

Explore

The Xanamem® Pipeline

Alzheimer’s
Disease

Major Depressive
Disorder

Fragile X
Syndrome

Diseases to be studied

Phase 2 Pathway

Outlook

Mild cognitive
impairment in early

Alzheimer’s Disease

Find out more

XanaMIA (IND)

Part A: 10mg, 5mg, Placebo Older Volunteers: cognition
Part B: Patients with early stages of AD: cognitive enhancement and supporting assessments

Multiple Phase 2b/3 trials

Diseases to be studied

Phase 2 Pathway

Outlook

Depression

with cognitive impairment

Find out more

Study preparation

XanaMDD
Phase 2 randomized trial

Potential to treat both depression and related cognitive impairment

Diseases to be studied

Phase 2 Pathway

Outlook

Anxiety, sleep & behavioral problems in

Fragile X Syndrome

Find out more

XanaFX (IND)

Proof-of-concept in adolescent and young adult males

Pending alternative funding or partnership

Stay updated

If you would like to receive our latest news and updates, you can join our email distribution list. Simply register your details.


    Back
    to top